Patient-reported Outcomes And Health-care Resource Utilization In Patients With Psoriasis Treated With Etanercept: Continuous Versus Interrupted Treatment
arthritis; atopic-dermatitis; Business & Economics; clinical trial; depression; double-blind; efficacy; etanercept; Health Care Sciences & Services; health-care resource utilization; monotherapy; phase-iii trial; plaque psoriasis; psoriasis; quality-of-life; quality-of-life; therapy; tumor necrosis factor
Gelfand J M; Kimball A B; Mostow E N; Chiou C F; Patel V; Xia H A; Freundlich B; Stevens S R
Value in Health
2008
2008-05
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1111/j.1524-4733.2007.00251.x" target="_blank" rel="noreferrer noopener">10.1111/j.1524-4733.2007.00251.x</a>
Successful treatment of alopecia universalis with alefacept: A case report and review of the literature
Dermatology; tumor-necrosis-factor; areata; etanercept; factor-alpha
Alopecia universalis often responds poorly to standard therapies. We report how a novel treatment option, alefacept, was successfully used in the management of a 21-year-old woman with alopecia universalis. The patient responded with complete regrowth of scalp and body hair after a single 12-week treatment course of alefacept. In addition, a review of the literature was performed pertaining to the use of biologic agents in the treatment of alopecia areata/universalis to determine which agents have a potential role in the treatment of this often refractory disease.
Bui K; Polisetty S; Gilchrist H; Jackson S M; Frederic J
Cutis
2008
2008-05
Journal Article or Conference Abstract Publication
n/a
Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
Humans; Treatment Outcome; Severity of Illness Index; Risk Assessment; Evidence-Based Medicine; Patient Selection; Ustekinumab; Antibodies; Anti-Inflammatory Agents/adverse effects/*therapeutic use; Etanercept; Immunoglobulin G/adverse effects/*therapeutic use; Immunosuppressive Agents/adverse effects/*therapeutic use; Psoriasis/*drug therapy/immunology; Receptors; Humanized; Monoclonal; Monoclonal/adverse effects/*therapeutic use; Tumor Necrosis Factor/*therapeutic use
IMPORTANCE OF THE FIELD: TNF-alpha inhibitors such as etanercept have been used for psoriasis for years. A fairly well defined efficacy and safety profile has developed. A new biologic agent, ustekinumab, an IL-12 and IL-23 inhibitor, has recently been released in the US for the treatment of moderate-to-severe psoriasis. The purpose of this article is to compare the efficacy and safety profiles of ustekinumab and etanercept. AREAS COVERED IN THIS REVIEW: We examined safety and efficacy data regarding ustekinumab and etanercept from clinical reports, a head-to-head trial, review articles, and databases and registries from the last 20 years. WHAT THE READER WILL GAIN: Evidence is reviewed about the efficacy for the treatment of psoriasis as well as the safety profiles for both agents, ustekinumab and etanercept. TAKE HOME MESSAGE: Both drugs have data to confirm efficacy and safety in patients with moderate-to-severe psoriasis in the short-term. The limited long-term data on the safety profile of ustekinumab requires careful judgment on the clinician's part, weighing well-defined benefits and potential unknown risks.
Uhlenhake Elizabeth E; Feldman Steven R
Expert opinion on biological therapy
2010
2010-07
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1517/14712598.2010.487061" target="_blank" rel="noreferrer noopener">10.1517/14712598.2010.487061</a>